MOMENTUM 3 Trial Summary: Mehra et al. randomized 366 patients with advanced HF (NYHA class III-IV, LVEF ≤ 25%), inotrope dependant, cardiac index < 2.2 without inotropes to either HeartMate III (centrifugal-flow LVAD) or HeartMate II (axial-flow LVAD). Their objective was to assess if is a magnetically levitated centrifugal-flow LVAD is superior to an axial-flow LVAD with regards to reoperation for device malfunction or disabling stroke in patients with advanced HF. The results showed the superiority of HeartMate III in terms of freedom from device failure. No differences in stroke were noticed. The authors of MOMENTUM 3 trial concluded that implantation of a fully magnetically levitated centrifugal-flow pump was associated with better outcomes at 6 months than was implantation of an axial-flow pump, primarily because of the lower rate of reoperation for pump malfunction.
Want to read more posts?